

LIST OF FIGURES

Fig. No.	Title	Page No.
2.1	Methods for preparation of Nanoparticles	26
3.1	Scan of Etoposide in Methanolic PBS	87
3.2	Calibration Plot of Etoposide in Methanolic PBS	88
3.3	Scan of Etoposide in Chloroform	91
3.4	Calibration Plot of Etoposide in Chloroform	92
3.5	Scan of Cytarabine in PBS	96
3.6	Calibration curve of Cytarabine in PBS	97
4.1	Mean Particle Size distribution and PDI of nanoparticles of Batch No H6	110
4.2a	Contour plot for response of MPS for X1 (homogenization pressure) and X2 (no. of homogenization cycles)	113
4.2b	Response Surface Plot for MPS for X1 (homogenization pressure) and X2 (no. of homogenization cycles)	113
4.3	Effect of process parameters (Homogenization pressure and Number of Homogenization cycles) during Homogenization on mean particle size and Pdl of formed nanoparticles.	114
4.4a	Contour plot of EE of ETO-PLGA NP	120
4.4b	Surface Response of EE of ETO-PLGA NP	120
4.5a	Contour plot for MPS of ETO-PLGA NP	124
4.5b	Surface Response of MPS of ETO-PLGA NP	124
4.6	Zeta potential distribution of ETO loaded PLGA nanoparticle batch no ENP5	127
4.7	Contour plot showing Zeta potential values: Combined Effect of Surfactant Concentration and drug loading	128
4.8	Influence of pH on zeta potential	129
4.9	Effect of Cryoprotectant on MPS after Lyophilization	131
4.10	DSC thermogram of Etoposide, PLGA and Etoposide loaded Nanoparticles	132
4.11	XRD of Etoposide, PLGA and Etoposide loaded Nanoparticles	133
4.12	SEM of Etoposide loaded PLGA NP	134

4.13	In Vitro Drug Release Profile of Etoposide and Etoposide loaded Nanoparticles	136
4.14	Drug Release Fitted to Higuchi Model	137
4.15	First order plot of Log cumulative % drug remaining Vs Time of ENP2 and ENP5	138
4.16	Korsmeyer-Peppas model for ENP2 and ENP5, Log (Mt/M ∞) is plotted against Log time t	138
4.17	Effect of storage condition at 2-8°C on Mean Particle Size of Etoposide loaded NP in AD and FD	140
4.18	Effect of storage condition at 25°C on Mean Particle Size of Etoposide loaded NP in AD and FD	141
4.19	Effect of storage condition at 40°C on Mean Particle Size of Etoposide loaded NP in AD and FD	142
4.20a	Effect of storage at 2-8°C, 25°C and 40°C on drug content of Etoposide loaded NP (ENP5) in FD and AD state	143
4.20b	Effect of storage at 2-8°C, 25°C and 40°C on drug content of Etoposide loaded NP (ENP2) in FD and AD state	144
4.21	¹ H NMR spectra of PLGA-mPEG copolymer	148
4.22	FT-IR spectra of (a) PLGA, (b) mPEG and (c) PLGA-mPEG	149
4.23	FT-IR spectra of (a) PLGA, (b) Pluronic F-68 and (c) PLGA-PLURONIC	150
4.24a	Surface plot for MPS PLGA-MPEG NP	155
4.24b	Contour plot for MPS PLGA-MPEG NP	155
4.25a	Surface plot %EE MPEG NP	160
4.25b	Contour plot %EE MPEG NP	160
4.26	Zeta potential of PLGA-mPEG NP (Batch No. EPMPEG NP6)	161
4.27	Effect of surfactant concentration on Zeta potential of PLGA-mPEG NP	162
4.28	Size distribution of ETO-PLGA-Pluronic NP	164
4.29	Zeta potential of PLGA-Pluronic NP	166
4.30	XRD of (a)Etoposide, (b) Physical mixture of ETO-PLGA-mPEG, (c) Etoposide loaded PLGA-mPEG NP and (d)ETO loaded PLGA-Pluronic NP	168
4.31	SEM of Etoposide loaded PLGA-mPEG NP (A) and PLGA-Pluronic NP (B)	169

4.32	In Vitro Drug Release Profile of Etoposide pure drug, Etoposide loaded PLGA-mPEG NP and Etoposide loaded PLGA-Pluronic Nanoparticles	171
4.33	Drug Release Fitted to Higuchi Model	172
4.34	Korsmeyer-Peppas model for EPMPEG NP and EPPLU NP, Log (Mt/M ∞) is plotted against Log time t	172
4.35	Effect of storage at 2-8°C on Mean Particle Size of EPMPEG NP and EPPLU NP in AD and FD	174
4.36	Effect of storage at 25°C on Mean Particle Size of EPMPEG NP and EPPLU NP in AD and FD	175
4.37	Effect of storage at 40°C on Mean Particle Size of EPMPEG NP and EPPLU NP in AD and FD	176
4.38	Effect of storage at 2-8°C, 25°C and 40°C on Assay of Etoposide loaded PLGA-mPEG NP in AD and FD	177
4.39	Effect of storage condition at 2-8°C, 25°C and 40°C on Assay of ETO loaded PLGA-Pluronic NP in AD and FD	178
5.1	Flow diagram for formulation of NP	184
5.2a	Contour plot for MPS	192
5.2b	Surface Response of MPS	192
5.3a	Contour plot for response of MPS against X1(drug: polymer ratio) and X2 (stirring time) values ranging from -1 to +1.	197
5.3b	Surface response plot for MPS against X1(drug: polymer ratio) and X2 (stirring time) values ranging from -1 to +1.	198
5.4a	Contour plot of EE	202
5.4b	Surface Response of EE	202
5.5	Size distribution graph of Cytarabine loaded PLGA NP batch No. CPNP15	203
5.6	Zeta potential of CYT loaded PLGA NP (B. No. CPNP15)	203
5.7a	Contour plot for MPS	208
5.7b	Surface Response of MPS	208
5.8a	Contour plot of EE	212
5.8b	Surface Response of EE	212
5.9	SEM of Cyt-PLGA NP and Cyt-MPEG NP.	215
5.10	XRD of CYT, Cyt-PLGA NP and Cyt-PLGA-MPEG NP	216
5.11	DSC thermogram of (A) cytarabine, (B) PLGA, (C) Cyt-PLGA NP	217

5.12	In Vitro Drug Release Profile of Cytarabine pure drug, CPM NP and CPNP	219
5.13	First Order Plot	220
5.14	Drug Release Fitted to Higuchi Model	220
5.15	Korsmeyer-Peppas model for CPM NP and CPNP, Log (Mt/M ∞) is plotted against Log time t	221
5.16	Effect of storage at 2-8°C, 25°C and 40°C on drug content of Lyophilized Cytarabine loaded PLGA NP and Cytarabine loaded PLGA-mPEG NP	223
5.17	Effect of storage condition at 2-8°C, 25°C and 40°C on Mean Particle Size of Lyophilized Cytarabine loaded PLGA NP and Cytarabine loaded PLGA-mPEG NP	224
6.1	% Viability of L1210 cells by MTT Assay using Plain drug etoposide (ETO), and Etoposide loaded NPs ETO-PLGA NP, ETO-PLGA-MPEG NP and ETO-PLGA-PLU NP.	232
6.2	% Viability of DU145 cells by MTT Assay using Plain drug etoposide (ETO), and Etoposide loaded NPs ETO-PLGA NP, ETO-PLGA-MPEG NP and ETO-PLGA-PLU NP.	233
6.3a	IC ₅₀ values of ETO, ETO-PLGA NP, ETO-PLGA-MPEG NP and ETO-PLGA-PLU NP for L1210 cells	234
6.3b	IC ₅₀ values of ETO, ETO-PLGA NP, ETO-PLGA-MPEG NP and ETO-PLGA-PLU NP for DU145 cells	234
6.4	% Viability of L1210 cells by MTT Assay using CYT, CYT-PLGA NP, CYT-PLGA-MPEG NP.	239
6.5	% Viability of DU145 cells by MTT Assay using CYT, CYT-PLGA NP, CYT-PLGA-MPEG NP.	240
6.6a	IC ₅₀ values of CYT, CYT-PLGA NP, CYT-PLGA-MPEG NP for L1210 cells	241
6.6b	IC ₅₀ values of CYT, CYT-PLGA NP, CYT-PLGA-MPEG NP for DU145 cells	241
6.7	DU145 Cell uptake efficiency (%) of PLGA, PLGA-MPEG and PLGA-PLURONIC NP at different time of 0.5, 1, 2 and 4 h at NP concentration = 100 µg/ml.	247
6.8	DU145 Cell uptake efficiency (%) of PLGA, PLGA-MPEG and PLGA-PLURONIC NP at different NP Concentration of 50, 100, 200 and 250 µg/ml. Incubation time is 4h.	247
6.9	L1210 Cell uptake efficiency (%) of PLGA, PLGA-MPEG and PLGA-PLURONIC NP at different time of 0.5, 1, 2 and 4 h at NP concentration = 100 µg/ml.	248

6.10	L1210 Cell uptake efficiency (%) of PLGA, PLGA-MPEG and PLGA-PLURONIC NP at different NP Concentration of 50, 100, 200 and 250 µg/ml. Incubation time is 4h.	248
6.11	Confocal microscope image showing cellular uptake of coumarin loaded PLGA NP at different time interval on L1210 cell lines	249
6.12	Confocal microscope image showing cellular uptake of coumarin loaded PLGA NP at different time interval on DU145 cell lines	250
6.13	stack confocal microscopy images of PLGA NP showing uptake in DU 145 cells.	251
6.14	Z stack Confocal microscopy images of PLGA-mPEG NP showing uptake in DU 145 cells	252
6.15	stack confocal microscopy images of PLGA-Pluronic NP showing uptake in DU 145 cells.	253
6.16	Z stack confocal microscopy images of PLGA-PLURONIC NP showing uptake in L1210 cells	254
6.17	Z stack confocal microscopy images of PLGA-mPEG NP showing uptake in L1210 cells	255
6.18	Comparison of Fluorescence image (F), Differential image (D) and overlap of Fluorescence Difference image (F-D) in L1210 cells for uptake of PLGA-mPEG NP	256
6.19a	Flow cytometric scan of L1210 cell lines (Control)	257
6.19b	Flow cytometric scan of L1210 cell lines using PLGA NPs	257
6.19c	Flow cytometric scan of L1210 cell lines using PLGA-MPEG NPs	258
6.19d	Flow cytometric scan of L1210 cell lines using PLGA-PLURONIC NPs	258
6.20	Flow cytometric scan of DU145 cell lines using PLGA NP, PLGA-MPEG NP and PLGA-PLU NP	259
7.1	Concentrations of ^{99m} Tc- Eto, ^{99m} Tc- Eto-PLGA NP ₁₀₅ and ^{99m} Tc- Eto-PLGA NP ₁₆₀ in the blood of Balb/c mice at 1h, 4h and 24h interval post injection.	278
7.2	Concentrations of ^{99m} Tc- Eto, ^{99m} Tc- Eto-PLGA NP ₁₀₅ and ^{99m} Tc- Eto-PLGA NP ₁₆₀ in the Liver and Spleen of Balb/c mice at 1h, 4h and 24h interval post injection.	279
7.3	Concentrations of ^{99m} Tc- Eto, ^{99m} Tc- Eto-PLGA NP ₁₀₅ and ^{99m} Tc- Eto-PLGA NP ₁₆₀ in the lungs of Balb/c mice at 1h, 4h and 24h interval post injection.	280

7.4	Brain concentrations of ^{99m}Tc - Eto, ^{99m}Tc - Eto-PLGA NP ₁₀₅ and ^{99m}Tc - Eto-PLGA NP ₁₆₀ in Balb/c mice at 1h, 4h and 24h interval post injection.	281
7.5	Bone concentrations of ^{99m}Tc - Eto, ^{99m}Tc - Eto-PLGA NP ₁₀₅ and ^{99m}Tc - Eto-PLGA NP ₁₆₀ in Balb/c mice at 1h, 4h and 24h interval post injection.	282
7.6	Blood concentrations of ^{99m}Tc -Eto-PLGA-PLU NP and ^{99m}Tc -Eto-PLGA-mPEG NP in Balb/c mice at 1h, 4h and 24h interval post injection.	285
7.7	Liver, Spleen and Lungs concentrations of ^{99m}Tc -Eto-PLGA-PLU NP and ^{99m}Tc -Eto-PLGA-mPEG NP in Balb/c mice at 1h, 4h and 24h interval post injection.	286
7.8	Brain concentrations of ^{99m}Tc -Eto-PLGA-PLU NP and ^{99m}Tc -Eto-PLGA-mPEG NP in Balb/c mice at 1h, 4h and 24h interval post injection.	287
7.9	Bone concentrations of ^{99m}Tc -Eto-PLGA-PLU NP and ^{99m}Tc -Eto-PLGA-mPEG NP in Balb/c mice at 1h, 4h and 24h interval post injection.	288
7.10	Blood concentrations of ^{99m}Tc -Cyt-PLGA NP and ^{99m}Tc -Cyt-PLGA-mPEG NP in Balb/c mice at 1h, 4h and 24h interval post injection.	293
7.11a	Liver and Spleen concentrations of ^{99m}Tc -Cyt-PLGA NP and ^{99m}Tc -Cyt-PLGA-mPEG NP in Balb/c mice at 1h, 4h and 24h interval post injection.	295
7.11b	Lung concentrations of ^{99m}Tc -Cyt-PLGA NP and ^{99m}Tc -Cyt-PLGA-mPEG NP in Balb/c mice at 1h, 4h and 24h interval post injection.	295
7.12	Brain concentrations of ^{99m}Tc -Cyt-PLGA NP and ^{99m}Tc -Cyt-PLGA-mPEG NP in Balb/c mice at 1h, 4h and 24h interval post injection.	296
7.13	Bone concentrations of ^{99m}Tc -Cyt-PLGA NP and ^{99m}Tc -Cyt-PLGA-mPEG NP in Balb/c mice at 1h, 4h and 24h interval post injection.	297
7.14	Blood clearance of ^{99m}Tc - Eto, ^{99m}Tc -Eto-PLGA NP ₁₀₅ , ^{99m}Tc - Eto-PLGA NP ₁₆₀ and ^{99m}Tc - Eto-PLGA-mPEG NP in Rats	301
7.15	Blood clearance of ^{99m}Tc -Cyt, ^{99m}Tc - Cyt-PLGA NP and ^{99m}Tc -Cyt-PLGA-mPEG NP in Rats	303
